<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150771</url>
  </required_header>
  <id_info>
    <org_study_id>031-201-00104</org_study_id>
    <nct_id>NCT03150771</nct_id>
  </id_info>
  <brief_title>Study to Determine the Pharmacokinetics, Safety &amp; Tolerability of Aripiprazole in Adults With Schizophrenia</brief_title>
  <official_title>A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Aripiprazole 2 Month Intramuscular Depot Administered Gluteally in Adult Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will determine the Pharmacokinetics, safety and tolerability of single-dose
      Aripiprazole administered intramuscularly in adults with schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) [safety and tolerability]</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>AEs will be monitored to assess safety and tolerability of drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Tests [safety and tolerability]</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>Hematology, clinical chemistry &amp; urinalysis tests will be performed to assess the safety and tolerability of drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms (ECGs) [Safety and tolerability]</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>Heart rate, RR, PR, WRS and WT intervals will be monitored to assess the safety and tolerability of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs [safety and tolerability]</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>Systolic/diastolic blood pressure, heart rate and body temperature will be monitored to assess the safety and tolerability of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidality via Columbia-Suicide Severity Rating Scale (C-SSRS) [safety and tolerability]</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>C-SSRS score will be monitored throughout the trial to assess the safety and tolerability of drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extrapyramidal Symptoms (EPS) Rating Scales</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>EPS score will be monitored to assess safety and tolerability of drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Assessment of Injection Site</measure>
    <time_frame>Screening Days -30 to Day 182 post dose/Early Termination</time_frame>
    <description>The injection site will be monitored to assess the safety and tolerability of drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) Scores for Pain Perception</measure>
    <time_frame>Day 1 to Day 28 post dose</time_frame>
    <description>VAS score will be monitored to assess safety and tolerability of drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 182/Early Termination</time_frame>
    <description>The maximum plasma concentration of drug at injection site will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - time of maximum plasma concentration (tmax)</measure>
    <time_frame>Day 1 to Day 182/Early Termination</time_frame>
    <description>The amount of time that the maximum plasma concentration of drug at injection site will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - area under concentration-time curve (AUC) calculated from time zero to time t (AUCt)</measure>
    <time_frame>Day 1 to Day 182/Early Termination</time_frame>
    <description>AUCt will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole to determine average concentration of drug over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC calculated from time to infinity</measure>
    <time_frame>Day 1 to Day 182/Early Termination</time_frame>
    <description>AUCinfinity will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole to determine total drug exposure over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Terminal-phase elimination half-life (t1/2,z)</measure>
    <time_frame>Day 1 to Day 182/Early Termination</time_frame>
    <description>t1/2,z will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole to determine drug persistence in the body</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole; single; gluteal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole; single; gluteal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Abilify Maintena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female individuals between 18 and 64 years, inclusive, at screening with a
             current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of
             Mental Disorders: edition 5 (DSM-5)

          -  Body mass index (BMI) between 18 and 35 kg/m^2 at screening

          -  Male and female subjects who are surgically sterile, female subjects who have been
             postmenopausal for at least 12 consecutive months prior to screening or male/female
             subjects who agree to remain abstinent or practice 2 of the approved birth control
             methods from screening for at least 150 days after dose of Investigational Medical
             Product (IMP) for female subjects or 180 days after dose of IMP for male subjects.

          -  Documented history of previously tolerating Aripiprazole per investigator's judgment.

        Exclusion Criteria:

          -  Met DSM-5 criteria for substance use disorder within past 180 days

          -  Positive drug screen for drugs of abuse

          -  Use of more than 1 antipsychotic medication at screening or baseline, except for oral
             Aripiprazole administered during tolerability testing and current antipsychotic
             medication

          -  Subjects may not receive varenicline beyond the screening visit.

          -  Subjects who had participated in any clinical trial involving a psychotropic
             medication within 1 month prior to administration of IMP

          -  Major surgery within 30 days prior to administration of IMP or surgery during the
             trial

          -  Subjects at significant risk of committing suicide based on history, psychiatric exams

          -  Subjects currently in an acute relapse of schizophrenia

          -  Subjects with a current DSM-5 diagnosis other than schizophrenia

          -  Subjects with a history of neuroleptic malignant syndrome, seizure disorder, or
             clinically significant tardive dyskinesia

          -  Subjects who have had electroconvulsive therapy within 2 months prior to
             administration of IMP

          -  Females who are breast-feeding and/or who have a positive pregnancy test result prior
             to receiving IMP

          -  History of or current hepatitis or Acquired Immunodeficiency Syndrome or carriers of
             Hepatitis B surface antigen (HBsAG), Hepatitis C antigen (anti-HCV) and/or Human
             Immunodeficiency Virus (HIV) antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

